General Psychiatry
General Psychiatry RSS Feed RSS

TCPR_QA_Kramer-headshot_400x400.jpg
Expert Q&A

Looking Back on Prozac

September 3, 2024
Peter D. Kramer, MD

TCPR_QA_Kramer-headshot_400x400.jpgPeter D. Kramer, MD

Emeritus Professor of Psychiatry and Human Behavior, Brown University. Author of eight books, including the runaway bestseller Listening to Prozac (Viking Adult, 1993) and Death of the Great Man (Post Hill Press, 2023).

Dr. Kramer has no financial relationships with companies related to this material.

Dr. Kramer examines how certain antidepressants can alter personality traits, while also exploring the ethical concerns and long-term effects of these changes.


Read More
Clinical Update

Gepirone: A First Look

September 3, 2024
Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Learn about the risks and efficacy of gepirone (Exxua) for treating MDD.



Read More
TCPR_September2024_Issue.png
Audio Issue

Listen to The Carlat Psychiatry Report, September 2024, Volume 22, Issue 9, “Antidepressants”

September 1, 2024

Listen to the full text of the issue read aloud by Gregory Malzberg, MD. Gepirone (Exxua) gets a critical review. The Neuroscience-Based Nomenclature reclassifies psych meds, and Peter Kramer reflects on whether SSRIs change personality 30 years after his classic Listening to Prozac.  


Read More
Depression_Augmention_Thumnail.jpg

Personalized Antidepressant Treatments: Augmentation Options for Different Depression Subtypes

August 25, 2024
Deepti Anbarasan, MD., David Liebers, MD, and Greg Malzberg, MD
In this video, we explore the latest breakthroughs in antidepressant augmentation, showing how personalized medicine can enhance outcomes for patients with various forms of depression. Whether your patient is facing anxious depression, depression with insomnia, or psychotic depression, this video offers evidence-based strategies that incorporate augmenation options such as lithium for depression, esketamine for depression, and quetiapine for depression.
Read More
TCPR_August2024_Issue.png
Audio Issue

Listen to The Carlat Psychiatry Report, August 2024, Volume 22, Issue 8, “Suicide”

August 23, 2024

Listen to the full text of the issue read aloud by Gregory Malzberg, MD. In this issue, David Jobes shows us how to empower patients while collaboratively assessing suicidality. Eight ways to treat OCD when SSRIs fail. Antipsychotic dosing in mania vs. schizophrenia, and all you need to know about a popular at-home treatment for depression: Transcranial direct stimulation (tDCS).


Read More
Vilazodone Review Medication Guide.jpg

Vilazodone Review | Mechanism • Faster Onset? • Better for Anxiety? • Sexual Side-effects?

August 14, 2024
Chris Aiken, MD. and Greg Malzberg, MD
Vilazodone, also known by its brand name Viibryd, became available as a generic in June 2022 after 11 years of market exclusivity. With the introduction of the Viibryd generic, the price of this multimodal antidepressant has significantly decreased, making it more accessible. However, the critical question remains: is vilazodone worth prescribing?
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.